09:45 AM EST - Acerus Pharmaceuticals Corporation : Announced today an update relative to the Company’s NATESTO® business. The Company announced that Hyundai Pharm Co., Ltd. has officially launched the commercialization of NATESTO® in South Korea.Hyundai, Acerus’ licensee for South Korea, officially launched NATESTO® at the Korean Symposium on Sexual Medicine and Andrology. Hyundai plans to continue to ramp up launch activities throughout the remainder of 2019 with both seminars to key physicians and an ongoing presence at medical congresses. This confirms the first commercial launch of NATESTO® outside North America. Acerus Pharmaceuticals Corporation
shares T.ASP are trading unchanged at $0.11.
